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Viral hepatitis is inflammation of the liver 
caused by one of five viruses — hepatitis A 
virus (HAV), hepatitis B virus (HBV), hepatitis 
C virus (HCV), hepatitis D virus (HDV) and 
hepatitis E virus (HEV).  In the United States, 
hepatitis A, B and C are the most common 
types of viral hepatitis, while hepatitis D and 
E are less prevalent.  Generally speaking, 
viral hepatitis can cause acute onset of 
nausea, jaundice and abdominal pain.  More 
specifically, HBV and HCV infection can 
result in a chronic infection attributed to 
increased risk of developing chronic liver 
disease and liver cancer.  Currently, safe 
and effective vaccines exist only for the 
prevention of HAV and HBV.  
Although case rates have declined during 
the last decade, viral hepatitis continues 
to be a disease of major public health 
concern, specifically in terms of morbidity 
and mortality.  A recent report released by 
the Institute of Medicine (IOM) estimates 
that approximately 5.3 million people, or 
2% of the US population, are living with 
chronic hepatitis B or hepatitis C, and 
attributes approximately 150,000 deaths per 
year to viral hepatitis-related liver disease.  
However, the IOM report also concluded that 
hepatitis B and C are not widely recognized 
as a serious public health problem and that 
the resources allocated to viral hepatitis 
prevention, control and surveillance 
programs are consistently inadequate.1  
Early identification of the virus is crucial 
to effective case management and the 
prevention of further disease transmission.  
Laboratories that perform diagnostic 
hepatitis testing play a vital role in 
identifying cases of the disease.  In order to 
characterize the role that the nation’s public 
health laboratories play in the prevention, 
control and surveillance of viral hepatitis, 
the Association of Public Health Laboratories 
(APHL) conducted the 2009 APHL Hepatitis 
Testing Survey in the summer of 2009.  This 
issue brief summarizes the results of that 
survey.
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The survey data reveal that the majority 
of public health laboratories in the United 
States continue to play a major role in the 
provision of HAV, HBV and/or HCV testing 
and that HDV, HEV and liver enzyme testing 
are not currently offered by US public 
health laboratories.  While the majority of 
laboratories report being compliant with 
current testing recommendations, the 
data did reveal an opportunity to increase 
awareness of  the 
recommendations 




and Result Reporting 
of Antibody to 
Hepatitis C Virus.  
This highlights 
the importance 
of periodically reminding public health 
laboratories of current hepatitis testing 
recommendations.2  APHL will continue to 
explore areas where member participation 
in hepatitis activities, including training and 
guidelines development, can be expanded to 
improve quality laboratory practice.
 
Method
The 2009 APHL Hepatitis Testing Survey was 
launched in June and closed in July 2009 
to assess the hepatitis testing practices, 
capacities and capabilities of the nation’s 
state public health laboratories (SPHLs).  
The 21-question survey was developed by 
members of the APHL Infectious Disease 
Committee along with the Centers for 
Disease Control and Prevention’s (CDC) 
Division of Viral Hepatitis, and was 
administered through MRInterview, a web-
based survey instrument.  
State public health laboratories in each 
of the 50 states and Washington, DC 
were invited to participate in the survey.  
Laboratories were asked to report on their 
viral hepatitis testing activities from January 
1, 2008 – December 31, 2008. APHL received 
responses from 41 (80%) of the SPHLs invited 
to participate in the survey.  
Viral hepatitis testing in sphls
Thirty-six (88%) of the respondents provide 
(i.e., perform or refer) some type of viral 
hepatitis testing to identify hepatitis A, 
B and/or C infection. Five (12%) of the 
respondents do not provide any hepatitis 
testing.  Only 15 (42%) public health 
laboratories report offering hepatitis panels, 
the most common being panels for acute 
hepatitis and prenatal screening. 
Of the 36 laboratories that offer viral 
hepatitis testing, 27 (75%) provide testing 
for hepatitis A, 34 (94%) for hepatitis B 
and 31 (86%) for hepatitis C.  None of the 
respondents reported providing hepatitis D, 
hepatitis E or liver enzyme testing.  Figure 1 
provides an illustration of these results.  
Twenty-three (64%) of the 36 responding 
laboratories offering viral hepatitis testing 
provide testing for hepatitis A, B and C.  
Six responding laboratories offer testing 
for hepatitis B and C solely, while four 
respondent laboratories offer testing for 
only hepatitis A and B.  Two respondents test 
only for hepatitis C and one respondent only 
offers hepatitis B testing. figure 1. number of state public health laboratories providing testing for 
each type of viral hepatitis (n=41).
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virAL HePAtitis testing survey rePort  May 2010 3
Funding sources
Public health laboratories receive funding 
for viral hepatitis testing from a variety of 
sources.  However, 58% of the 36 laboratories 
that provide viral hepatitis testing report 
that the funding received is insufficent for 
laboratory testing needs.  The majority of 
responding laboratories (28, or 78%) use 
state general budget funds to support at 
least part of their hepatitis testing program.  
Thirteen (36%) hepatitis testing laboratories 
charge fees to at least a portion of their 
specimen submitters for hepatitis testing 
services.  None of the laboratories that 
responded to the survey report having a 
budget-line item dedicated for hepatitis 
testing.  A complete summary of funding 
data is located in Figure 2.  
HePATITIS A TeSTIng PrAcTIceS
Testing for hepatitis A virus (HAV) was 
the least frequently reported type of viral 
hepatitis testing offered among survey-
participating laboratories, with 27 state 
public health laboratories providing this 
service.  Currently, there are two serological 
tests used for the detection of hepatitis A: 
IgM anti-HAV and total HAV.3  Both assays 
detect the presence of antibodies against 
HAV and confirm a diagnosis of the virus.  
While all 27 laboratories that offer hepatitis 
A testing provide anti-HAV IgM testing, only 
19 (70%) of those laboratories also provide 
anti-HAV total testing.  Figure 3 summarizes 
the number of laboratories performing 
both types of HAV testing in-house versus 
those that contract the testing to a referral 
laboratory.
haV testing VoluMe 
Quantitative comparison of HAV testing 
volumes (as well as hepatitis B and C) across 
states is challenging, as regions have varying 
population sizes and incidence rates as well 
as varying levels of testing conducted in the 
private sector.  For example, testing volume 
for anti-HAV total varied from a low of 2 
specimens to a high of 58,790 samples, with 
the median number of anti-HAV total tests 
equal to 292.  Because several responding 
states reported considerably larger testing 
volumes than others, there is a disparity 
between the maximum and the median 
volume.  Comparatively, tests for anti-HAV 
IgM were reported in fewer numbers than 
the anti-HAV total test – with a range of 1 
to 1,250 (median 42.5) specimens received – 
among SPHLs that responded to this survey. 
Funding Sources for Hepatitis Testing at SPHLs (2008)
Funding Source















figure 2. Percentage of state public health laboratories that receive various 
types of funding sources for viral hepatitis testing, out of responding 
laboratories that offer hepatitis testing services (n=36).
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figure 3. Types of Hepatitis A testing offered by state public health 
laboratories in 2008 (n=27).
58% of the 36 laboratories that provide viral hepatitis testing report that the funding 
received is insufficent for laboratory testing needs.
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haV test Kits
Among participating laboratories, Diasorin® 
kits are most frequently used for hepatitis 
A testing, followed by Abbott® diagnostic 
kits.  Figure 4 provides details on the use of 
various hepatitis A test kits in SPHLs.  
HePATITIS b TeSTIng PrAcTIceS
Detection of HBV infection is the most 
common type of viral hepatitis testing 
offered among participating SPHLs, with 
34 laboratories that provide testing.  HBV 
is diagnosed using one or more serological 
assays that identify the presence of hepatitis 
B antigen or antibody in an individual.  
The stage of infection is determined by 
interpreting the results of these assays in 
combination.  The assays used include those 
for detecting hepatitis B surface antigen 
(HBsAg),  hepatitis B surface antibody (anti-
HBs), total hepatitis B core antibody (anti-
HBc) and IgM antibody to hepatitis B core 
antigen (anti-HBc, IgM).4  The anti-HBs test 
is also used to determine whether or not an 
individual has been successfully vaccinated 
against HBV.
Anti-HBs testing is the most commonly 
offered hepatitis B assay in public health 
laboratories with 33 respondents providing 
the test, followed by the HBsAg assay offered 
by 32 of the participating laboratories.  While 
30 public health laboratories offer the HBsAg 
assay in-house, only 22 (73%) routinely offer 
a confirmatory neutralization assay on all 
specimens that test positive for HBsAg.  
Additional types of hepatitis B tests 
include both qualitative and quantitative 
hepatitis B DNA PCR testing and hepatitis 
B virus genotyping; however, while a few 
laboratories offer these tests through a 
reference lab, none of the responding 
laboratories reported performing these tests 
in-house.  Figure 5 illustrates the various 
types of hepatitis B testing offered in US 
state public health laboratories.
hBV testing VoluMe
As seen with testing volumes reported for 
HAV, there were significant differences 
noted in the testing volumes among the 
respondents.  During 2008, state public 
health laboratories that offer hepatitis B 
surface antigen (HBsAg) testing reported a 
minimum of 77 specimens, and a maximum 
of 66,728 specimens. The median was 14,780. 
For the total hepatitis B core antibody 
(anti-HBc) specimen volume, labs reported 
a range of 3 to 59,174 specimens, with a 
figure 5. Types of hepatitis b testing offered by state public health 
laboratories in 2008 (n=34).
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figure 4. Hepatitis A diagnostic kit usage of state public health 
laboratories offering HAv testing in 2008 (n=27).
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median of 1,032.  The hepatitis B surface 
antibody (anti-HBs) test included reported 
volumes of as few as 11 specimens, as many 
as 59,456 and a median value of 707. Of the 
four hepatitis B detection assays commonly 
used in SPHLs, the anti-HBc IgM assay was 
used least frequently, with the smallest 
volume of tests reported equal to 8, the 
largest number of tests equal to 984 and a 
median value of 108.  
hBV test Kits
Public health laboratories reported using 
a wide variety of hepatitis B test kits.  
While no particular kit manufacturer was 
consistently more popular across all the 
HBV markers, public health laboratories 
report using DiaSorin® and Abbott® test 
kits most frequently.  Figure 6 illustrates kit 
usage by hepatitis B analysis.  
HePATITIS c TeSTIng PrAcTIceS
HCV was the second most commonly tested 
hepatitis virus among survey respondents, 
with 31 (86%) public health laboratories 
offering hepatitis C testing.  Serologic and 
molecular assays are currently available for 
the diagnosis of HCV infection.  Serological 
testing assesses the presence of antibodies 
to the virus to indicate exposure to 
HCV.5  Anti-HCV testing includes initial 
screening with an immunoassay. CDC 
recommendations indicate that specimens 
yielding positive anti-HCV screening test 
results should supplement testing with 
the anti-HCV strip immunoblot assay 
(RIBA).  A positive supplemental test result 
is interpreted as anti-HCV positive, while 
a negative RIBA result is interpreted as 
negative and indicates a false positive 
screening test result.  All 31 of the 
respondents that offer hepatitis C testing 
provide anti-HCV screening, while 16 
responding laboratories report providing the 
supplemental anti-HCV assay.  
Molecular assays determine the presence 
(qualitative) or amount (quantitative) of HCV 
RNA in a particular serum specimen.5  Only 
nine public health laboratories reported 
providing either qualitative or quantitative 
molecular assay detection methods.   
Genotyping may be done to distinguish 
which of the six different HCV genotypes is 
present in the test sample;5 only four public 
health laboratories report providing this 
type of testing.  
use oF signal-to-cut-oFF (s/co) 
ratios in hcV testing
In 2003, CDC’s Division of Viral Hepatitis 
published Guidelines for Laboratory 
Testing and Result Reporting of Antibody to 
Hepatitis C Virus.2  The guidelines provide 
recommendations for anti-HCV screening 
and supplemental testing, and include 
an option for reflex supplemental testing 
that is based on the s/co ratios of anti-HCV 
positive screening tests.  This advice—to 
perform supplemental anti-HCV testing 
only on specimens with values below a 
given s/co ratio—provides laboratories 
with an opportunity to reduce the cost and 
burden of supplemental testing necessary to 
confirm infection.  
Although most respondents reported using 
a s/co ratio of 3.8 as the threshold, there was 
variation in the way SPHLs use and report 


















































figure 6. Hepatitis b diagnostic test kit usage of state public health 
laboratories offering Hbv testing in 2008 (n=34).
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the s/co ratio.  Thirteen laboratories reported 
that only specimens below the specified s/co 
ratio receive supplemental anti-HCV testing.  
Six laboratories reported that supplemental 
testing is performed only by physician 
request, regardless of the s/co value.  Seven 
public health laboratories only perform and 
report anti-HCV screening results, referring 
all patients to care for supplemental testing; 
however, two of those laboratories include 
language recommending supplemental 
testing if the s/co ration is below the 
predetermined threshold.  Three laboratories 
reported performing supplemental anti-HCV 
testing on all positive anti-HCV screening 
specimens regardless of s/co ratio.  
 
hcV testing VoluMe
As previously noted, viral hepatitis testing 
volume across states shows wide variation, 
and the data for HCV are no exception.  For 
example, the lowest number of anti-HCV 
screening tests performed was 8 and the 
largest was 59,207, with a median of 1,345 
tests.  As expected, confirmatory anti-HCV 
tests were reported in lower volumes than 
the screening anti-HCV, with a minimum 
of 4 tests, a maximum of 719 tests, and a 
median of 90 tests. 
The number of quantitative HCV molecular 
assays performed by SPHLs in 2008 ranged 
from 141 to 183, with a median of 162.  The 
largest volume of qualitative HCV molecular 
assays conducted in SPHLs was 896, with 
a median of 313.  As previously reported, 
only four laboratories receive specimens for 
genotyping, and the number of specimens 
was very low, ranging from 40 to 80, with a 
median of 60.
hcV diagnostic Kit usage
In most cases, the public health laboratories 
that responded to this survey are using 
standard FDA-approved diagnostic kits from 
a variety of manufacturers.  For a detailed 
categorization of diagnostic kits used for 
HCV testing, please see Figure 8. 
conclusions
This survey provides insights into the 
current viral hepatitis testing practices 
in state public health laboratories in the 
United States.  The fact that the majority 
of responding public health laboratories 
provide HAV, HBV and/or HCV testing 
suggests APHL should explore areas 
where member participation in hepatitis 
activities, including training and guidelines 
development, can be expanded. 
According to CDC’s website, both HDV 
and HEV are thought to be uncommon in 
the United States.  This may point to the 
reason for the lack of HDV and HEV testing 
conducted in United States public health 
laboratories.  The lack of a commercially 
available test for HEV diagnosis may also 
contribute to the lack of testing laboratories. 
Testing for HDV and HEV in the United 
States is mainly performed in commercial 
laboratories.  
















































figure 7. Types of hepatitis c testing offered in state public health 
laboratories in 2008 (n=31).
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The majority of laboratories surveyed 
were familiar with, and followed the 
recommendations in, the 2003 Guidelines for 
Laboratory Testing and Result reporting of Antibody 
to Hepatitis C Virus.2  APHL will look for ways 
to increase awareness about the hepatitis C 
recommendations among its membership in 
an attempt to obtain 100% compliance among 
public health laboratories.
Adequate funding for hepatitis testing remains 
a significant challenge for many public health 
laboratories.  The wide availability of viral 
hepatitis testing in the private sector often 
leads to low testing volumes in public health 
laboratories, leading to diminished capacity and 
occasionally elimination of the testing service.  
Public health laboratories continue to play an 
important role in supporting public health 
detection and control measures for hepatitis 
A, B, and C viruses, providing testing in-house 
using a variety of test methods and assays 
and, in some cases, referring testing to another 
laboratory. In the future, APHL will continue to 
seek opportunities to work with federal, state, 
local and nongovernmental partners to address 
viral hepatitis testing challenges and improve 
viral hepatitis testing practices in the nation’s 
public health laboratories.
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figure 8. Hepatitis c diagnostic kit usage in public health laboratories offering 
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association of public Health laboratories
Analysis. Answers. Action.
the association of public health laboratories is a national 
non-profit located in silver spring, Md, that is dedicated 
to working with members to strengthen governmental 
laboratories with a public health mandate. By promoting 
effective programs and public policy, aphl strives to 
provide public health laboratories with the resources and 
infrastructure needed to protect the health of us residents 
and to prevent and control disease globally. 
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